In the high-stakes world of drug development, time isn’t just money, it’s measured in human lives. Yet, for decades, the process of finding the right location to test a new life-saving therapy has remained stuck in a pre-digital purgatory.
While we can find a five-star hotel in a remote corner of the world in seconds, pharmaceutical giants and Contract Research Organizations (CROs) are often still relying on dusty spreadsheets and multi-million dollar data contracts to decide where to run their trials.
The result? A staggering 80% of clinical trials fail to meet their original enrollment timelines. This feasibility gap doesn’t just stall innovation; it costs the industry billions and keeps patients waiting for cures that are stuck in administrative limbo.
Today, Ryght AI is looking to shatter that bottleneck with the launch of RyghtSites.com, a platform they call the world’s first free, AI-powered search engine for clinical trial sites.
Moving Beyond the Spreadsheet Era
The traditional method of site selection is a grueling exercise in manual research. Identifying a capable clinic with the right patient demographic and a proven track record can take three to six months. In an industry where a single day’s delay in drug launch can represent millions in lost revenue, this lag is unsustainable.
“Traditional site selection methods are costing the industry valuable time and resources,” says Simon Arkell, CEO and Co-Founder of Ryght AI. “RyghtSites.com is our answer to giving sponsors and CROs a smarter starting point.”
By opening up access to a global database of over 100,000 clinical research sites across 192 countries, Ryght is effectively commoditizing what used to be a high-priced gatekeeper service.
The Power of the AI Site Twin
What sets RyghtSites apart from a standard directory is its underlying architecture. The platform is powered by AI Site Twins, digital replicas of research sites that allow for agentic ranking.
Instead of a simple keyword search, users input specific trial parameters, including disease indication, biomarkers, and phase requirements. The AI then scans its network to surface the sites most likely to succeed based on real-world trial history and current capacity.
Key features of the new platform include:
- Massive Scale: Coverage of 100,000+ locations globally.
- Precision Filtering: Sorting by complex diseases, specific biomarkers, and regional regulations.
- Full Lifecycle Support: Optimization for everything from Phase 1 safety trials to massive Phase 4 post-market studies.
- Instant Portability: The ability to download ranked lists via CSV for immediate integration into trial planning.
A 26-Day Miracle: The ROI of Speed
The most compelling argument for this shift isn’t just the free price tag; it’s the performance. In a recent case study, a leading global CRO utilized Ryght’s platform to tackle an oncology site selection campaign.
Historically, such a campaign would take roughly 180 days to finalize. Using Ryght’s AI-driven approach, the CRO compressed that timeline into just 26 days. More impressively, they didn’t just meet their recruitment goal, they exceeded it by 330%.
Democratizing Data to Accelerate Innovation
By making this high-level intelligence free to the public, Ryght AI is positioning itself as a disruptor to legacy data vendors who have long charged six-figure sums for similar access.
Backed by a heavy-hitting roster of investors, including AIX Ventures, Accenture Ventures, Foothill Ventures, and others, Ryght is betting that by removing the friction at the starting line of a trial, they can accelerate the entire ecosystem.
As the pharmaceutical industry moves toward more agentic workflows, where AI doesn’t just suggest data but actively automates whole workflows, RyghtSites.com represents a significant first step towards that future.
For an industry desperate for efficiency, the message from Laguna Beach is clear: the data is here, the AI is ready, and finally, the search is free.
Companies can try now at: http://RyghtSites.com.
